Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

Impact of the COVID-19 Pandemic on Chronic Neurological Disorders: Focus on Patients with Dementia

Author(s): Maria Antonietta Barbieri, Gianluca Bagnato, Carmelo Ioppolo, Antonio Giovanni Versace and Natasha Irrera*

Volume 21, Issue 10, 2022

Published on: 07 March, 2022

Page: [1017 - 1026] Pages: 10

DOI: 10.2174/1871527321666220111124928

Price: $65

Abstract

The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) represents a public health problem worldwide. COVID-19 triggers a maladaptive cytokine release commonly referred to as cytokine storm syndrome with increased production of proinflammatory cytokines, which also appears to contribute to chronic neuroinflammation and neurodegenerative disorders’ appearance, including multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease. In this context, SARS-CoV-2 might enter the central nervous system through binding with the angiotensin converting enzyme 2 receptors which are highly expressed in glial cells and neurons. For this reason, an association between COVID-19, its dependent cytokine storm, and the development and/or progression of neurodegenerative disorders might be evaluated. Therefore, the aim of this review was to assess the impact of COVID-19 on neurodegenerative disorders, focusing on the possible increased mortality risk and/or deterioration of the clinical course of pre-existing chronic neurological diseases in patients with dementia.

Keywords: COVID-19, neurological disorders, multiple sclerosis, parkinson’s disease, alzheimer’s disease, dementia.

« Previous Next »
Graphical Abstract

[1]
Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol 2020; 92(4): 401-2.
[http://dx.doi.org/10.1002/jmv.25678] [PMID: 31950516]
[2]
Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382(13): 1199-207.
[http://dx.doi.org/10.1056/NEJMoa2001316] [PMID: 31995857]
[3]
Wiersinga WJ, Rhodes A, Cheng AC, et al. pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): A review. JAMA. 2020; 324(8): 782-793.
[http://dx.doi.org/10.1001/jama.2020.12839]
[4]
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727-33.
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]
[5]
Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2020; 6: 1-14.
[PMID: 33024307]
[6]
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270-3.
[http://dx.doi.org/10.1038/s41586-020-2012-7] [PMID: 32015507]
[7]
Lam TTY, Jia N, Zhang YW, et al. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature 2020; 583(7815): 282-5.
[http://dx.doi.org/10.1038/s41586-020-2169-0] [PMID: 32218527]
[8]
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395(10224): 565-74.
[http://dx.doi.org/10.1016/S0140-6736(20)30251-8] [PMID: 32007145]
[9]
WHO. Naming the coronaviruse disease (COVID-19) and the virus that causes it. Online (Bergh) 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it
[10]
Gorbalenya AE, Baker S, Baric R, et al. The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 5(4): 536-44.
[http://dx.doi.org/10.1038/s41564-020-0695-z] [PMID: 32123347]
[11]
WHO Coronavirus Disease (COVID-19). Available at: https://covid19.who.int
[12]
European Centre for Disease Prevention and Control. Latest situation update, epidemiological curve and global distribution 2020.
[13]
McAloon C, Collins Á, Hunt K, et al. Incubation period of COVID-19: A rapid systematic review and meta-analysis of observational research. BMJ Open 2020; 10(8): e039652.
[http://dx.doi.org/10.1136/bmjopen-2020-039652] [PMID: 32801208]
[14]
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
[15]
Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA 2020; 323(13): 1239-42.
[http://dx.doi.org/10.1001/jama.2020.2648] [PMID: 32091533]
[16]
Tan E, Song J, Deane AM, et al. Global impact of coronavirus disease 2019 infection requiring admission to the ICU. Chest 2020; S0012-3692(20): 34906-0.
[17]
Abate SM, Ali SA, Mantfardo B, et al. Rate of intensive care unit admission and outcomes among patients with coronavirus: A systematic review and meta-analysis. PLoS One 2020; 15: 1-19.
[18]
Quah P, Li A, Phua J. Mortality rates of patients with COVID-19 in the intensive care unit: A systematic review of the emerging literature. Crit Care Critical Care 2020; 24(1): 285.
[http://dx.doi.org/10.1186/s13054-020-03006-1] [PMID: 32498689]
[19]
Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis. Int J Infect Dis 2020; 94: 91-5.
[http://dx.doi.org/10.1016/j.ijid.2020.03.017] [PMID: 32173574]
[20]
Liu W, Tao ZW, Wang L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl) 2020; 133(9): 1032-8.
[http://dx.doi.org/10.1097/CM9.0000000000000775] [PMID: 32118640]
[21]
Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020; 323(16): 1574-81.
[http://dx.doi.org/10.1001/jama.2020.5394] [PMID: 32250385]
[22]
Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med 2020; 8(5): 475-81.
[http://dx.doi.org/10.1016/S2213-2600(20)30079-5] [PMID: 32105632]
[23]
Aoyama H, Uchida K. Respiratory characteristics and related intraoperative ventilatory management for patients with COVID ‑ 19 pneumonia. J Anesth 2020; 35: 356-60.
[http://dx.doi.org/10.1007/s00540-020-02845-0]
[24]
Zhao Q, Meng M, Kumar R, et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis. Int J Infect Dis 2020; 96: 131-5.
[http://dx.doi.org/10.1016/j.ijid.2020.04.086] [PMID: 32376308]
[25]
Robba C, Battaglini D, Pelosi P, Rocco PRM. Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2. Expert Rev Respir Med 2020; 14(9): 865-8.
[http://dx.doi.org/10.1080/17476348.2020.1778470] [PMID: 32567404]
[26]
Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 Cytokine Storm; What We Know So Far. Front Immunol 2020; 11: 1446.
[http://dx.doi.org/10.3389/fimmu.2020.01446] [PMID: 32612617]
[27]
Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev 2020; 53: 25-32.
[http://dx.doi.org/10.1016/j.cytogfr.2020.05.003] [PMID: 32446778]
[28]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[29]
Mannino F, Bitto A, Irrera N. Severe acute respiratory syndrome coronavirus-2 induces cytokine storm and inflammation during coronavirus disease 19: Perspectives and possible therapeutic approaches. Front Pharmacol 2020; 11: 592169.
[http://dx.doi.org/10.3389/fphar.2020.592169] [PMID: 33633566]
[30]
Mao L, Jin H, Wang M, et al. neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020; 77(6): 683-90.
[http://dx.doi.org/10.1001/jamaneurol.2020.1127] [PMID: 32275288]
[31]
Varatharaj A, Thomas N, Ellul MA, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: A UK-wide surveillance study. Lancet Psychiatry 2020; 7(10): 875-82.
[http://dx.doi.org/10.1016/S2215-0366(20)30287-X] [PMID: 32593341]
[32]
Kumar S, Dwivedi D, Chopra M. COVID-19 outbreak: Neurological manifestations beyond cough and fever. CNS Neurol Disord Drug Targets 2021; 20(2): 101-4.
[PMID: 33222680]
[33]
Javed A. Neurological associations of SARS-CoV-2 infection: A systematic review. CNS Neurol Disord Drug Targets 2021. [Online ahead of Print]
[http://dx.doi.org/10.2174/1871527320666210216121211] [PMID: 33593267]
[34]
Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 2009; 4: 47.
[http://dx.doi.org/10.1186/1750-1326-4-47] [PMID: 19917131]
[35]
Desforges M, Coupanec A, Le , Dubeau P, et al. Human coronaviruses and other respiratory viruses: Underestimated opportunistic pathogens of the central nervous system? Viruses 2019; 12:14(1): 1-28.
[36]
Paybast S, Emami A, Koosha M, Baghalha F. Novel coronavirus disease (COVID-19) and central nervous system complications: What neurologists need to know. Acta Neurol Taiwan 2020; 29(1): 24-31.
[PMID: 32285431]
[37]
Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 2020; 87: 18-22.
[http://dx.doi.org/10.1016/j.bbi.2020.03.031] [PMID: 32240762]
[38]
Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: Tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 2020; 11(7): 995-8.
[http://dx.doi.org/10.1021/acschemneuro.0c00122] [PMID: 32167747]
[39]
Serrano-Castro PJ, Estivill-Torrús G, Cabezudo-García P, et al. Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: A delayed pandemic? Neurologia 2020; 35(4): 245-51.
[http://dx.doi.org/10.1016/j.nrleng.2020.04.002] [PMID: 32364119]
[40]
Antonini A, Leta V, Teo J, Chaudhuri KR. Outcome of Parkinson’s disease patients affected by COVID-19. Mov Disord 2020; 35(6): 905-8.
[http://dx.doi.org/10.1002/mds.28104] [PMID: 32347572]
[41]
Bianchetti A, Rozzini R, Guerini F, et al. Clinical presentation of COVID19 in dementia patients. J Nutr Health Aging 2020; 24(6): 560-2.
[http://dx.doi.org/10.1007/s12603-020-1389-1] [PMID: 32510106]
[42]
Ferini-Strambi L, Salsone M. COVID-19 and neurological disorders: Are neurodegenerative or neuroimmunological diseases more vulnerable? J Neurol 2020; 268(2): 409-19.
[43]
Meshkat S, Salimi A, Joshaghanian A, Sedighi S, Sedighi S, Aghamollaii V. Chronic neurological diseases and COVID-19: Associations and considerations. Transl Neurosci 2020; 11(1): 294-301.
[http://dx.doi.org/10.1515/tnsci-2020-0141] [PMID: 33335769]
[44]
Bhaskar S, Bradley S, Israeli-Korn S, et al. Chronic neurology in COVID-19 Era: Clinical considerations and recommendations from the REPROGRAM consortium. Front Neurol 2020; 11: 664.
[http://dx.doi.org/10.3389/fneur.2020.00664] [PMID: 32695066]
[45]
Sharma S, Batra S, Gupta S, Sharma VK, Rahman MH, Kamal MA. Persons with co-existing neurological disorders: risk analysis, considerations and management in covid-19 pandemic. CNS Neurol Disord Drug Targets 2022; 21(3): 228-34.
[http://dx.doi.org/10.2174/1871527320666210308113457] [PMID: 33687889]
[46]
Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler J 2020; 26(14): 1816-21.
[47]
Dobson R, Giovannoni G. Multiple sclerosis - A review. Eur J Neurol 2019; 26(1): 27-40.
[http://dx.doi.org/10.1111/ene.13819] [PMID: 30300457]
[48]
Caballero-Villarraso J, Jiménez-Jiménez MJ, Escribano BM, Agüera E, Santamaría A, Túnez I. Implications of vitamin D in multiple sclerosis and other neurodegenerative processes: Bibliometric analysis and systematic review. CNS Neurol Disord Drug Targets 2019; 18(6): 478-90.
[http://dx.doi.org/10.2174/1871527318666190703102330] [PMID: 31269889]
[49]
Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010; 133(Pt 7): 1900-13.
[http://dx.doi.org/10.1093/brain/awq076] [PMID: 20423930]
[50]
Ghasemi N, Razavi S, Nikzad E. Multiple sclerosis: Pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J 2017; 19(1): 1-10.
[PMID: 28367411]
[51]
Pourcher V. What are the infectious risks with disease-modifying drugs for multiple sclerosis and how to reduce them? A review of literature. Rev Neurol (Paris) 2020; 176(4): 235-43.
[http://dx.doi.org/10.1016/j.neurol.2019.08.012] [PMID: 31983473]
[52]
Castelo-Branco A, Chiesa F, Conte S, et al. Infections in patients with multiple sclerosis: A national cohort study in Sweden. Mult Scler Relat Disord 2020; 45: 102420.
[53]
Wijnands JMA, Kingwell E, Zhu F, et al. Infection-related health care utilization among people with and without multiple sclerosis. Mult Scler 2017; 23(11): 1506-16.
[http://dx.doi.org/10.1177/1352458516681198] [PMID: 28273769]
[54]
Nelson RE, Xie Y, DuVall SL, et al. Multiple sclerosis and risk of infection-related hospitalization and death in US veterans. Int J MS Care 2015; 17(5): 221-30.
[http://dx.doi.org/10.7224/1537-2073.2014-035] [PMID: 26472943]
[55]
Capkun G, Dahlke F, Lahoz R, et al. Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database. Mult Scler Relat Disord 2015; 4(6): 546-54.
[http://dx.doi.org/10.1016/j.msard.2015.08.005] [PMID: 26590661]
[56]
Hillman LJ, Burns SP, Kraft GH. Neurological worsening due to infection from renal stones in a multiple sclerosis patient. Mult Scler 2000; 6(6): 403-6.
[http://dx.doi.org/10.1177/135245850000600608] [PMID: 11212137]
[57]
Haji Akhoundi F, Sahraian MA, Naser Moghadasi A. Neuropsychiatric and cognitive effects of the COVID-19 outbreak on multiple sclerosis patients. Mult Scler Relat Disord 2020; 41: 102164.
[http://dx.doi.org/10.1016/j.msard.2020.102164] [PMID: 32388452]
[58]
Mares J, Hartung HP. Multiple sclerosis and COVID-19. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2020; 164(3): 217-25.
[http://dx.doi.org/10.5507/bp.2020.033] [PMID: 32686774]
[59]
Boziki MK, Mentis AA, Shumilina M, Makshakov G, Evdoshenko E, Grigoriadis N. COVID-19 immunopathology and the central nervous system: Implication for multiple sclerosis and other autoimmune diseases with associated demyelination. Brain Sci 2020; 10(6): 1-11.
[http://dx.doi.org/10.3390/brainsci10060345] [PMID: 32512702]
[60]
Chen R, Wang K, Yu J, et al. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in human and mouse brain. Front Neurol 2021; 11: 573095.
[http://dx.doi.org/10.3389/fneur.2020.573095] [PMID: 33551947]
[61]
Hascup ER, Hascup KN. Does SARS-CoV-2 infection cause chronic neurological complications? Geroscience 2020; 42(4): 1083-7.
[http://dx.doi.org/10.1007/s11357-020-00207-y] [PMID: 32451846]
[62]
Palao M, Fernández-Díaz E, Gracia-Gil J, Romero-Sánchez CM, Díaz-Maroto I, Segura T. Multiple sclerosis following SARS-CoV-2 infection. Mult Scler Relat Disord 2020; 45: 102377.
[http://dx.doi.org/10.1016/j.msard.2020.102377] [PMID: 32698095]
[63]
Sadeghmousavi S, Rezaei N. COVID-19 and multiple sclerosis: Predisposition and precautions in treatment. SN Compr Clin Med 2020; 2(10): 1-6.
[http://dx.doi.org/10.1007/s42399-020-00504-9] [PMID: 32895640]
[64]
Sormani MP. An Italian programme for COVID-19 infection in multiple sclerosis. Lancet Neurol 2020; 19(6): 481-2.
[http://dx.doi.org/10.1016/S1474-4422(20)30147-2] [PMID: 32359409]
[65]
Bsteh G, Bitschnau C, Hegen H, et al. Multiple sclerosis and covid-19: how many are at risk? Eur J Neurol 2022; 28(10): 3369-74.
[http://dx.doi.org/10.1111/ene.14555] [PMID: 32978860]
[66]
Ramezani N, Ashtari F, Bastami EA, et al. Fear and anxiety in patients with multiple sclerosis during COVID-19 pandemic; report of an Iranian population. Mult Scler Relat Disord 2021; 50: 102798.
[http://dx.doi.org/10.1016/j.msard.2021.102798] [PMID: 33571791]
[67]
Willis MD, Robertson NP. Multiple sclerosis and the risk of infection: Considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2. J Neurol 2020; 267(5): 1567-9.
[http://dx.doi.org/10.1007/s00415-020-09822-3] [PMID: 32303837]
[68]
Giovannoni G, Hawkes C, Lechner-scott J, et al. The COVID-19 pandemic and the use of MS disease-modifying therapies Mult Scler Relat Disord 2020; 39: 102073.
[http://dx.doi.org/10.1016/j.msard.2020.102073]
[69]
Rahmani H, Davoudi-Monfared E, Nourian A, et al. Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial. Int Immunopharmacol 2020; 88: 106903.
[http://dx.doi.org/10.1016/j.intimp.2020.106903] [PMID: 32862111]
[70]
Davoudi-Monfared E, Rahmani H, Khalili H, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob Agents Chemother 2020; 64(9): e01061-20.
[http://dx.doi.org/10.1128/AAC.01061-20] [PMID: 32661006]
[71]
Louapre C, Collongues N, Stankoff B, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol 2020; 77(9): 1079-88.
[http://dx.doi.org/10.1001/jamaneurol.2020.2581] [PMID: 32589189]
[72]
Fan M, Qiu W, Bu B, et al. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflammation 2020; 7(5): e787.
[73]
Marino BLB, de Souza LR, Sousa KPA, et al. Parkinson’s disease: A review from pathophysiology to treatment. Mini Rev Med Chem 2020; 20(9): 754-67.
[http://dx.doi.org/10.2174/1389557519666191104110908] [PMID: 31686637]
[74]
Reich SG, Savitt JM. Parkinson’s disease. Med Clin North Am 2019; 103(2): 337-50.
[http://dx.doi.org/10.1016/j.mcna.2018.10.014] [PMID: 30704685]
[75]
Del Prete E, Francesconi A, Palermo G, et al. Prevalence and impact of COVID-19 in Parkinson’s disease: Evidence from a multi- center survey in Tuscany region. J Neurol 2021; 268(4): 1179-87.
[http://dx.doi.org/10.1007/s00415-020-10002-6] [PMID: 32880722]
[76]
Kitani-Morii F, Kasai T, Horiguchi G, et al. Risk factors for neuropsychiatric symptoms in patients with Parkinson’s disease during COVID-19 pandemic in Japan. PLoS One 2021; 16(1 January): 1-13.
[77]
Janiri D, Petracca M, Moccia L, et al. COVID-19 pandemic and psychiatric symptoms: The impact on Parkinson’s disease in the elderly. Front Psychiatry 2020; 11: 581144.
[http://dx.doi.org/10.3389/fpsyt.2020.581144] [PMID: 33329124]
[78]
van der Kolk NM, de Vries NM, Kessels RPC, et al. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson’s disease: A double-blind, randomised controlled trial. Lancet Neurol 2019; 18(11): 998-1008.
[http://dx.doi.org/10.1016/S1474-4422(19)30285-6] [PMID: 31521532]
[79]
Helmich RC, Bloem BR. The impact of the COVID-19 pandemic on Parkinson’s disease: Hidden sorrows and emerging opportunities. J Parkinsons Dis 2020; 10(2): 351-4.
[http://dx.doi.org/10.3233/JPD-202038] [PMID: 32250324]
[80]
Anwar F, Naqvi S, Al-Abbasi FA, et al. Targeting COVID-19 in Parkinson’s patients: Drugs repurposed. Curr Med Chem 2020; 28(12): 2392-408.
[PMID: 32881656]
[81]
Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to- moderate forms of the coronavirus disease (COVID-19): A multicenter European study. Eur Arch Otorhinolaryngol 2020; 277(8): 2251-61.
[http://dx.doi.org/10.1007/s00405-020-05965-1] [PMID: 32253535]
[82]
Attademo L, Bernardini F. Are dopamine and serotonin involved in COVID-19 pathophysiology? Eur J Psychiatry 2021; 35(1): 62-3.
[http://dx.doi.org/10.1016/j.ejpsy.2020.10.004] [PMID: 33162632]
[83]
Rey NL, Wesson DW, Brundin P. The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases. Neurobiol Dis 2018; 109(Pt B): 226-48.
[http://dx.doi.org/10.1016/j.nbd.2016.12.013] [PMID: 28011307]
[84]
Schirinzi T, Landi D, Liguori C. COVID-19: Dealing with a potential risk factor for chronic neurological disorders. J Neurol 2021; 268(4): 1171-8.
[85]
Rey NL, George S, Steiner JA, et al. Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term. Acta Neuropathol 2018; 135(1): 65-83.
[http://dx.doi.org/10.1007/s00401-017-1792-9] [PMID: 29209768]
[86]
Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020; 71(15): 762-8.
[87]
Weyand CM, Goronzy JJ. Aging of the immune system: Mechanisms and therapeutic targets. Ann Am Thorac Soc 2016; 13(Suppl 5): S422-28.
[88]
De Virgilio A, Greco A, Fabbrini G, et al. Parkinson’s disease: Autoimmunity and neuroinflammation. Autoimmun Rev 2016; 15(10): 1005-11.
[http://dx.doi.org/10.1016/j.autrev.2016.07.022] [PMID: 27497913]
[89]
Ait Wahmane S, Achbani A, Ouhaz Z, Elatiqi M, Belmouden A, Nejmeddine M. The possible protective role of α-synuclein against severe acute respiratory syndrome coronavirus 2 infections in patients with Parkinson’s disease. Mov Disord 2020; 35(8): 1293-4.
[http://dx.doi.org/10.1002/mds.28185] [PMID: 32519352]
[90]
Papa SM, Brundin P, Fung VSC, et al. Impact of the COVID-19 pandemic on Parkinson’s disease and movement disorders. Mov Disord Clin Pract (Hoboken) 2020; 7(4): 357-60.
[http://dx.doi.org/10.1002/mdc3.12953] [PMID: 32373651]
[91]
Vignatelli L, Zenesini C, Belotti LMB, et al. Risk of hospitalization and death for COVID-19 in people with Parkinson’s disease or Parkinsonism. Mov Disord 2021; 36(1): 1-10.
[http://dx.doi.org/10.1002/mds.28408] [PMID: 33196119]
[92]
Scorza FA, Fiorini AC, Scorza CA, Finsterer J. Cardiac abnormalities in Parkinson’s disease and Parkinsonism. J Clin Neurosci 2018; 53: 1-5.
[http://dx.doi.org/10.1016/j.jocn.2018.04.031] [PMID: 29706419]
[93]
Fasano A, Cereda E, Barichella M, et al. COVID-19 in Parkinson’s disease patients living in Lombardy, Italy. Mov Disord 2020; 35(7): 1089-93.
[http://dx.doi.org/10.1002/mds.28176] [PMID: 32484584]
[94]
Hong CT, Hu HH, Chan L, Bai CH. Prevalent cerebrovascular and cardiovascular disease in people with Parkinson’s disease: A meta-analysis. Clin Epidemiol 2018; 10: 1147-54.
[http://dx.doi.org/10.2147/CLEP.S163493] [PMID: 30233249]
[95]
Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol 2020; 75(18): 2352-71.
[http://dx.doi.org/10.1016/j.jacc.2020.03.031] [PMID: 32201335]
[96]
de Siqueira JVV, Almeida LG, Zica BO, Brum IB, Barceló A, de Siqueira Galil AG. Impact of obesity on hospitalizations and mortality, due to COVID-19: A systematic review. Obes Res Clin Pract 2020; 14(5): 398-403.
[http://dx.doi.org/10.1016/j.orcp.2020.07.005] [PMID: 32736969]
[97]
Alqahtani JS, Oyelade T, Aldhahir AM, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: A rapid systematic review and meta-analysis. PLoS One 2020; 15(5): e0233147.
[http://dx.doi.org/10.1371/journal.pone.0233147] [PMID: 32392262]
[98]
Baille G, Chenivesse C, Perez T, et al. Dyspnea: An underestimated symptom in Parkinson’s disease. Parkinsonism Relat Disord 2019; 60: 162-6.
[http://dx.doi.org/10.1016/j.parkreldis.2018.09.001] [PMID: 30224267]
[99]
Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020; 92(6): 552-5.
[http://dx.doi.org/10.1002/jmv.25728] [PMID: 32104915]
[100]
Bhidayasiri R, Virameteekul S, Kim J-M, Pal PK, Chung SJ. COVID-19: An early review of its global impact and considerations for Parkinson’s disease patient care. J Mov Disord 2020; 13(2): 105-14.
[http://dx.doi.org/10.14802/jmd.20042] [PMID: 32344993]
[101]
Pinter B, Diem-Zangerl A, Wenning GK, et al. Mortality in Parkinson’s disease: A 38-year follow-up study. Mov Disord 2015; 30(2): 266-9.
[http://dx.doi.org/10.1002/mds.26060] [PMID: 25447933]
[102]
Bugalho P, Ladeira F, Barbosa R, et al. Motor and non-motor function predictors of mortality in Parkinson’s disease. J Neural Transm (Vienna) 2019; 126(11): 1409-15.
[http://dx.doi.org/10.1007/s00702-019-02055-3] [PMID: 31385098]
[103]
Curtis JA, Molfenter S, Troche MS. Predictors of residue and airway invasion in Parkinson’s disease. Dysphagia 2020; 35(2): 220-30.
[http://dx.doi.org/10.1007/s00455-019-10014-z] [PMID: 31028481]
[104]
van Wamelen DJ, Leta V, Johnson J, et al. Drooling in Parkinson’s disease: Prevalence and progression from the non-motor international longitudinal study. Dysphagia 2020; 35(6): 955-61.
[http://dx.doi.org/10.1007/s00455-020-10102-5] [PMID: 32130515]
[105]
Yu Y, Travaglio M, Popovic R, Leal NS, Martins LM. Alzheimer’s and Parkinson’s diseases predict different COVID-19 outcomes, a UK Biobank study. Geriatrics (Basel) 2021; 6(1): 10.
[http://dx.doi.org/10.3390/geriatrics6010010] [PMID: 33530357]
[106]
DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener 2019; 14(1): 32.
[http://dx.doi.org/10.1186/s13024-019-0333-5] [PMID: 31375134]
[107]
World Health Organization. Global action plan on the public health response to dementia 2017 - 2025. Geneva World Health Organ 2017; 52. Available from: https://apps.who.int/iris/bitstream/handle/10665/259615/9789241513487-eng.pdf?sequence=1
[108]
Schultz C, Del Tredici K, Braak H. Neuropathology of Alzheimer’s Disease.Alzheimer’s Disease. Current Clinical Neurology Totowa, NJ: Humana Press 2004.
[109]
Kumar R, Harilal S, Al-Sehemi AG, Mathew GE, Carradori S, Mathew B. The chronicle of COVID-19 and possible strategies to curb the pandemic. Curr Med Chem 2021; 28(15): 2852-86.
[http://dx.doi.org/10.2174/0929867327666200702151018] [PMID: 32614740]
[110]
Kobayashi R, Hayashi H, Kawakatsu S, et al. Recognition of the coronavirus disease 2019 pandemic and face mask wearing in patients with Alzheimer’s disease: An investigation at a medical centre for dementia in Japan. Psychogeriatrics 2020; 20(6): 923-5.
[http://dx.doi.org/10.1111/psyg.12617] [PMID: 33006226]
[111]
Xia X, Wang Y, Zheng J. COVID-19 and Alzheimer’s disease: How one crisis worsens the other. Transl Neurodegener 2021; 10(1): 15.
[http://dx.doi.org/10.1186/s40035-021-00237-2] [PMID: 33941272]
[112]
Brown EE, Kumar S, Rajji TK, Pollock BG, Mulsant BH. Anticipating and mitigating the impact of the COVID-19 pandemic on Alzheimer’s disease and related dementias. Am J Geriatr Psychiatry 2020; 28(7): 712-21.
[http://dx.doi.org/10.1016/j.jagp.2020.04.010] [PMID: 32331845]
[113]
Lara B, Carnes A, Dakterzada F, Benitez I, Piñol-Ripoll G. Neuropsychiatric symptoms and quality of life in Spanish patients with Alzheimer’s disease during the COVID-19 lockdown. Eur J Neurol 2020; 27(9): 1744-7.
[http://dx.doi.org/10.1111/ene.14339] [PMID: 32449791]
[114]
Martín-Jiménez P, Muñoz-García MI, Seoane D, et al. Cognitive impairment is a common comorbidity in deceased COVID-19 patients: A hospital-based retrospective cohort study. J Alzheimers Dis 2020; 78(4): 1367-72.
[http://dx.doi.org/10.3233/JAD-200937] [PMID: 33074239]
[115]
Carpanini SM, Torvell M, Morgan BP. Therapeutic inhibition of the complement system in diseases of the central nervous system. Front Immunol 2019; 10: 362.
[http://dx.doi.org/10.3389/fimmu.2019.00362] [PMID: 30886620]
[116]
Jevtic S, Sengar AS, Salter MW, McLaurin J. The role of the immune system in Alzheimer disease: Etiology and treatment. Ageing Res Rev 2017; 40: 84-94.
[http://dx.doi.org/10.1016/j.arr.2017.08.005] [PMID: 28941639]
[117]
Wadhwa R, Paudel KR, Mehta M, et al. Beyond the obvious: Smoking and respiratory infection implications on Alzheimer’s disease. CNS Neurol Disord Drug Targets 2020; 19(9): 698-708.
[http://dx.doi.org/10.2174/1871527319999200817112427] [PMID: 33109069]
[118]
Solana C, Tarazona R, Solana R. Immunosenescence of natural killer cells, inflammation, and Alzheimer’s disease. Int J Alzheimers Dis 2018; 2018(31287): 3128758.
[http://dx.doi.org/10.1155/2018/3128758] [PMID: 30515321]
[119]
Fiorino S, Gallo C, Zippi M, et al. Cytokine storm in aged people with CoV-2: possible role of vitamins as therapy or preventive strategy. Aging Clin Exp Res 2020; 32(10): 2115-31.
[http://dx.doi.org/10.1007/s40520-020-01669-y] [PMID: 32865757]
[120]
Roy ER, Wang B, Wan YW, et al. Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. J Clin Invest 2020; 130(4): 1912-30.
[http://dx.doi.org/10.1172/JCI133737] [PMID: 31917687]
[121]
Rahman MA, Islam K, Rahman S, Alamin M. Neurobiochemical cross-talk between COVID-19 and Alzheimer’s disease. Mol Neurobiol 2021; 58(3): 1017-23.
[http://dx.doi.org/10.1007/s12035-020-02177-w] [PMID: 33078369]
[122]
Isaia G, Marinello R, Tibaldi V, Tamone C, Bo M. Atypical presentation of covid-19 in an older adult with severe Alzheimer disease. Am J Geriatr Psychiatry 2020; 28(7): 790-1.
[http://dx.doi.org/10.1016/j.jagp.2020.04.018] [PMID: 32381283]
[123]
D’Adamo H, Yoshikawa T, Ouslander JG. Coronavirus disease 2019 in geriatrics and long-term care: The ABCDs of COVID-19. J Am Geriatr Soc 2020; 68(5): 912-7.
[http://dx.doi.org/10.1111/jgs.16445] [PMID: 32212386]
[124]
Naughton SX, Raval U, Pasinetti GM. Potential novel role of COVID-19 in Alzheimer’s disease and preventative mitigation strategies. J Alzheimers Dis 2020; 76(1): 21-5.
[http://dx.doi.org/10.3233/JAD-200537] [PMID: 32538855]
[125]
Europe Alzheimer. Dementia as a European priority. A Policy Overview 2020; 1-32. Available from: https://www.alzheimer-europe.org/EN/content/download/231512/1707786/file/Dementia%20as%20a%20European%20priority.pdf
[126]
Trevisan K, Cristina-Pereira R, Silva-Amaral D, Aversi-Ferreira TA. Theories of aging and the prevalence of Alzheimer’s disease. BioMed Res Int 2019; 2019(91714): 9171424.
[http://dx.doi.org/10.1155/2019/9171424] [PMID: 31317043]
[127]
Alzheimer’s Association Report. 2020 Alzheimer’s disease facts and figures. Alzheimers Dement 2020; 16(3): 391-460.
[http://dx.doi.org/10.1002/alz.12068]
[128]
Perrotta F, Corbi G, Mazzeo G, et al. COVID-19 and the elderly: Insights into pathogenesis and clinical decision-making. Aging Clin Exp Res Springer International Publishing 2020; 32(8): 1599-608.
[http://dx.doi.org/10.1007/s40520-020-01631-y] [PMID: 32557332]
[129]
Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA 2020; 323(14): 1335.
[http://dx.doi.org/10.1001/jama.2020.4344] [PMID: 32181795]
[130]
Covino M, De Matteis G, Santoro M, et al. Clinical characteristics and prognostic factors in COVID-19 patients aged ≥80 years. Geriatr Gerontol Int 2020; 20(7): 704-8.
[http://dx.doi.org/10.1111/ggi.13960] [PMID: 32516861]
[131]
Wang JH, Wu YJ, Tee BL, Lo RY. Medical comorbidity in Alzheimer’s disease: A nested case-control study. J Alzheimers Dis 2018; 63(2): 773-81.
[http://dx.doi.org/10.3233/JAD-170786] [PMID: 29660933]
[132]
Lall R, Mohammed R, Ojha U. What are the links between hypoxia and Alzheimer’s disease? Neuropsychiatr Dis Treat 2019; 15: 1343-54.
[http://dx.doi.org/10.2147/NDT.S203103] [PMID: 31190838]
[133]
Azarpazhooh MR, Amiri A, Morovatdar N, et al. Correlations between COVID-19 and burden of dementia: An ecological study and review of literature. J Neurol Sci Elsevier 2020; 416: 117013.
[http://dx.doi.org/10.1016/j.jns.2020.117013] [PMID: 32659508]
[134]
Ebihara S, Sekiya H, Miyagi M, Ebihara T, Okazaki T. Dysphagia, dystussia, and aspiration pneumonia in elderly people. J Thorac Dis 2016; 8(3): 632-9.
[http://dx.doi.org/10.21037/jtd.2016.02.60] [PMID: 27076964]
[135]
Kenerly MJ, Shah P, Patel H, et al. Altered mental status is an independent predictor of mortality in hospitalized COVID-19 patients. Ir J Med Sci 2022; 191(1): 21-26.
[PMID: 33566314]
[136]
Bauer K, Schwarzkopf L, Graessel E, Holle R. A claims data-based comparison of comorbidity in individuals with and without dementia. BMC Geriatr 2014; 14: 10.
[http://dx.doi.org/10.1186/1471-2318-14-10] [PMID: 24472217]
[137]
July J, Pranata R. Prevalence of dementia and its impact on mortality in patients with coronavirus disease 2019: A systematic review and meta-analysis. Geriatr Gerontol Int 2021; 21(2): 172-7.
[http://dx.doi.org/10.1111/ggi.14107] [PMID: 33340212]
[138]
Hwang J-M, Kim J-H, Park J-S, Chang MC, Park DH. Neurological diseases as mortality predictive factors for patients with COVID-19: A retrospective cohort study. Neurol Sci 2020; 41(9): 2317-4.
[139]
Coppolino G, Presta P, Nicotera R, et al. COVID-19 and renal disease in elderly patients. Geriatr Care 2020; 6(2).
[http://dx.doi.org/10.4081/gc.2020.9029]
[140]
Shahid Z, Kalayanamitra R, McClafferty B, et al. COVID-19 and older adults: what we know. J Am Geriatr Soc 2020; 68(5): 926-9.
[http://dx.doi.org/10.1111/jgs.16472] [PMID: 32255507]
[141]
Hariyanto TI, Putri C, Situmeang RFV, Kurniawan A. Dementia is a predictor for mortality outcome from coronavirus disease 2019 (COVID-19) infection. Eur Arch Psychiatry Clin Neurosci 2021; 271(2): 393-5.
[http://dx.doi.org/10.1007/s00406-020-01205-z] [PMID: 33104903]

Rights & Permissions Print Cite
Article Metrics
26
1
© 2024 Bentham Science Publishers | Privacy Policy